Challenges in assessing regional distribution of inhaled drug in the human lungs

Expert Opinion on Drug Delivery

Volumn 8, Issue 7, 2011, Pages 841-855

  Newman, Stephen ^a   Fleming, John ^b  

^a NHS Trust ^*  (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

gamma scintigraphy; positron emission tomography; radionuclide imaging; respiratory drug delivery; single photon emission computed tomography

Indexed keywords

TECHNETIUM 99M;

AEROSOL; GAMMA SCINTIGRAPHY; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG DEPOSIT; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THREE DIMENSIONAL IMAGING;

ADMINISTRATION, INHALATION; HUMANS; LUNG; PHARMACOKINETICS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 79959279686     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2011.577063     Document Type: Review

References (98)

1. Selroos O, Pietinalho A, Riska H. Delivery devices for inhaled asthma medication: clinical implications of differences in effectiveness. Clin Immunother 1996;6:293-9
2. Ruffin RE, Montgomery JM, Newhouse MT. Site of beta-adrenergic receptors in the respiratory tract: use of fenoterol administered by two methods. Chest 1978;74:256-60 (Pubitemid 9026243)
3. Collier JG, Dobbs RJ, Williams I. Salbutamol aerosol causes a tachycardia due to the inhaled rather than the swallowed fraction. Br J Clin Pharmacol 1980;9:273-4 (Pubitemid 10153919)
4. Barnes PJ, Pedersen S, Busse W.W. Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med 1998;157:S1-53
5. Dolovich MB. Measuring total and regional lung deposition using inhaled radiotracers. J Aerosol Med 2001;14(Suppl 1):S35-44 (Pubitemid 32172852)
6. Newman SP, Pitcairn GR, Hirst PH, Rankin L. Radionuclide imaging technologies and their use in evaluating asthma drug deposition in the lungs. Adv Drug Deliv Rev 2003;55:851-67 (Pubitemid 36776797)
7. Berridge MS, Lee Z, Heald DL. Regional distribution and kinetics of inhaled pharmaceuticals. Curr Pharm Des 2000;6:1631-51
8. Newman S, Anderson P, Byron P, et al. Respiratory drug delivery: essential theory and practice. Richmond: RDD Online/ Virginia Commonwealth University, 2009
9. Borgstrom L, Nilsson M. A method for determination of the absolute pulmonary bioavailability of inhaled drugs: terbutaline. Pharm Res 1990;7:1068-70 (Pubitemid 20366736)
10. Newman SP, Steed K, Hooper G, et al. Comparison of gamma scintigraphy and a pharmacokinetic technique for assessing pulmonary deposition of terbutaline sulphate delivered by pressurized metered dose inhaler. Pharm Res 1995;12:231-6
11. Hindle M, Chrystyn H. Determination of the relative bioavailability of salbutamol to the lung following inhalation. Br J Clin Pharmacol 1992;34:311-15
12. Scheuch G, Bennett W, Borgstrom L, et al. Deposition, imaging and clearance: what remains to be done? J Aerosol Med Pulm Drug Deliv 2010;23(Suppl 2):S39-57
13. Everard ML, Dolovich MB. In vivo measurement of lung dose. In: Bisgaard H, OCallaghan C, Smaldone GC, editors, Drug Delivery to the Lung. Marcel Dekker, New York; p. 173-209
14. Lee Z, Berridge MS, Nelson AD, Heald DL. The effect of scatter and attenuation on aerosol deposition as determined by gamma scintigraphy. J Aerosol Med 2001;14:167-83 (Pubitemid 32744349)
15. Fleming JS, Conway JH. Three-dimensional imaging of aerosol deposition. J Aerosol Med 2001;14:147-53 (Pubitemid 32744347)
16. Dolovich M, Nahmias C, Coates G. Unleashing the PET: 3D imaging of the lung. In: Dalby RN, Byron PR, Farr SJ, et al. editors, Respiratory Drug Delivery VII. Serentec Press, Raleigh; p. 215-30
17. Pritchard JN. The influence of lung deposition on clinical response. J Aerosol Med 2001;14(Suppl 1):S19-26 (Pubitemid 32172850)
18. Howarth PH. Why particle size should affect clinical response to inhaled therapy. J Aerosol Med 2001;14(Suppl 1):S27-34 (Pubitemid 32172851)
19. Bennett WD, Brown JS, Zeman KL, et al. Targeting delivery of aerosols to different lung regions. J Aerosol Med 2002;15:179-88 (Pubitemid 34827531)
20. Taylor G, Gumbleton M. Aerosols for macromolecule delivery: design challenges and solutions. Am J Drug Deliv 2004;2:143-55 (Pubitemid 39264434)
21. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part 1: physiological factors affecting therapeutic effectiveness of aerosolised medications. Br J Clin Pharmacol 2003;56:588-99 (Pubitemid 37491710)
22. Weibel ER. Morphometry of the Human Lung. Academic Press, New York; 1963
23. Fleming JS, Quint M, Bolt L, et al. Comparison of SPECT aerosol deposition data with twenty-four-hour clearance measurements. J Aerosol Med 2006;19:261-7 (Pubitemid 44735384)
24. Cherry SR, Sorenson JA, Phelps ME. Physics of nuclear medicine. Saunders, Philadelphia; 2003
25. Newman SP, Pitcairn GR. Gamma scintigraphy and SPECT. In: Lappin G, Temple S, editors, Radiotracers in Drug Development. Taylor and Francis, Boca Raton; 2006. p. 269-88
26. Walker PS, Petterson GL, Bondesson E, Conway JH. An advanced and detailed in vitro validation procedure for the radiolabelling of carrier-free terbutaline sulphate dry powder. J Aerosol Med 2001;14:227-36 (Pubitemid 32744354)
27. Roller CM, Schaefer NC, Zhang G, Daviskas SG. In vitro validation of 99mTc-HFA-FP delivered via pMDI-spacer. J Aerosol Med 2006;19:254-60 (Pubitemid 44735383)
28. Walker PS, Conway JH, Fleming JS, et al. Pulmonary clearance rate of two chemically different forms of inhaled pertechnetate. J Aerosol Med 2001;14:209-15 (Pubitemid 32744352)
29. Hasani A, Agnew JE, Toms N, et al. Scintigraphic assessment of lung drug deposition distribution using a radiolabelled drug surrogate: significance of radiolabel transport post deposition as a source of error. In: Drug Delivery to the Lungs X. The Aerosol Society, Portishead; 1999. p. 96-9
30. Marthin JM, Mortensen J, Pressler T, et al. Pulmonary radioaerosol mucociliary clearance in diagnosis of pulmonary ciliary dyskinesia. Chest 2007;132:966-76
31. Mortensen J, Lange L, Nyboe J, et al. Lung mucociliary clearance. Eur J Nucl Med 1994;21:953-61 (Pubitemid 24276575)
32. Coates AL, Green M, Leung K, et al. The challenges of quantitative measurement of lung deposition using 99mTc-DTPA from delivery systems with very different delivery times. J Aerosol Med 2007;20:320-30 (Pubitemid 47463185)
33. Smaldone GC. Radionuclide scanning, respiratory physiology and pharmacokinetics. J Aerosol Med 2001;14:135-7 (Pubitemid 32744345)
34. Newman SP, Chan H-K. In vitro - in vivo comparisons in pulmonary drug delivery. J Aerosol Med 2008;21:77-84
35. Borgstrom L, Olsson B, Thorsson L. Degree of throat deposition can explain the variability in lung deposition of inhaled drugs. J Aerosol Med 2006;19:473-83 (Pubitemid 46067766)
36. Smaldone GC. Deposition patterns of nebulized drugs: is the pattern important? J Aerosol Med 1994;7(Suppl 1):S25-31
37. Agnew JE. Characterizing lung aerosol penetration. J Aerosol Med 1991;4:237-49
38. Dolovich MB. Practical aspects of imaging techniques employed to study aerosol deposition and clearance. In: Hickey AJ, editor, Pharmaceutical Inhalation Aerosol Technology. 2nd edition. Marcel Dekker, New York; p. 171-213
39. Fleming JS, Sauret V, Conway JH, et al. Evaluation of the accuracy and precision of lung aerosol deposition measurements from single-photon emission computed tomography using simulation. J Aerosol Med 2000;13:187-98
40. Biddiscombe M, Underwood R, Meah S, Usmani O. Gamma scintigraphy: how should we measure regional lung deposition? European Respiratory Society Annual Congress, Barcelona, 2010, e-poster
41. Schroeter JD, Pritchard JN, Hwang D, Martonen TB. Airway identification within planar gamma camera images using computer models of lung morphology. Pharm Res 2005;22:1692-9 (Pubitemid 41355909)
42. Tossici-Bolt L, Fleming JS, Conway JH, Martonen TB. Analytical technique to recover the third dimension in planar imaging of inhaled aerosols: (1) impact on spatial quantification. J Aerosol Med 2006;19:565-79 (Pubitemid 46067774)
43. Pitcairn GR, Newman SP. Tissue attenuation corrections in gamma scintigrpahy. J AerosolMed 1997;3:187-98 (Pubitemid 27415413)
44. Macey DJ, Marshall R. Absolute quantitation of radiotracer uptake in the lungs using a gamma camera. J Nucl Med 1982;23:731-5
45. Fleming JS, Conway JH, Bolt L, Holgate ST. A comparison of planar scintigraphy and SPECT measurement of total lung deposition of inhaled aerosol. J Aerosol Med 2003;16:9-19 (Pubitemid 36457649)
46. Forge NI, Mountford PJ, ODoherty MJ. Quantification of technetium-99m lung radioactivity from planar images. Eur J Nucl Med 1993;20:10-15 (Pubitemid 23015330)
47. Fleming JS, Conway JH, Holgate ST, et al. Evaluation of the accuracy and precision of lung aerosol deposition measurements from planar imaging using simulation. Phys Med Biol 1998;43:2423-9 (Pubitemid 28372636)
48. Coates AL, Dinh L, MacNeish CF, et al. Accounting for radioactivity before and after nebulization of tobramycin to ensure accuracy of quantification of lung deposition. J Aerosol Med 2000;13:169-78
49. Taylor G, Warren SJ. Methods for tissue attenuation correction in inhalation pharmaceutical scintigraphy studies. In: Dalby RN, Byron PR, Peart J, et al. editors, Respiratory Drug Delivery 2010. Davis Healthcare International, River Grove, Illinois; 2010. p. 929-33
50. Moller W, Felten K, Meyer G, et al. Corrections in dose assessment of Tc-99m radiolabeled aerosol particles targeted to central human airways using planar gamma camera imaging. J Aerosol Med Pulm Drug Deliv 2009;22:45-54
51. Fleming JS, Conway JH, Majoral C, et al. The use of SPECT-CT to assess the fate of inhaled aerosol. J Aerosol Med Pulm Drug Deliv 2011;24:49-60
52. Newman SP, Hirst PH, Pitcairn GR, Clark AR. Understanding regional lung deposition in gamma scintigraphy. In: Dalby RN, Byron PR, Farr SJ, editors, Respiratory Drug Delivery VI. Interpharm Press, Buffalo Grove; p. 9-15
53. Fleming JS, Halson P, Conway J, et al. Three-dimensional description of pulmonary deposition of inhaled aerosol using data from multimodality imaging. J Nucl Med 1996;37:873-7 (Pubitemid 126447810)
54. Clark AR. Beyond the throat: preferred methods of assessing regional distribution in the lung. In: Dalby RN, Byron PR, Peart J, et al. editors, Respiratory Drug Delivery 2010. Davis Healthcare International, River Grove; p. 235-44
55. Camner P, Philipson K. Human alveolar deposition of 4 -m Teflon particles. Arch Environ Health 1978;36:171-5
56. Eberl S, Chan H-K, Daviskas E. SPECT imaging for radioaerosol deposition and clearance studies. J Aerosol Med 2006;19:8-20
57. Lawson RS. SPECT reconstruction. In: Mathematical Techniques in Nuclear Medicine IPEM Report 100, Institute of Physics and Engineering in Medicine, New York, 2011. p. 172-244
58. Glover W, Chan H-K, Eberl S, et al. Lung deposition of mannitol powder aerosol in healthy subjects. J Aerosol Med 2006;19:522-33
59. Fleming JS, Hashish AH, Conway JH, et al. Assessment of deposition of inhaled aerosol in the respiratory tract of man using three-dimensional multimodality imaging and mathematical modeling. J Aerosol Med 1996;9:317-27 (Pubitemid 26366899)
60. Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med 1998;39:904-11 (Pubitemid 28216748)
61. Fleming JS. Measuring drug deposition by airway generation in humans. In: Dalby RN, Byron PR, Peart J, et al. editors, Respiratory Drug Delivery IX. Davis Healthcare International, River Grove; 2004. p. 187-93
62. Phipps PR, Gonda I, Bailey DL, et al. Comparisons of planar and tomographic gamma scintigraphy to measure the penetration index of inhaled aerosols. Am Rev Respir Dis 1989;139:1516-23 (Pubitemid 19155515)
63. Bocher M, Balan A, Krausz Y, et al. Gamma camera-mounted anatomical X-ray tomography: technology, system characteristics and first images. Eur J Nucl Med 2000;27:619-27 (Pubitemid 30408762)
64. Fleming JS, Sauret V, Conway JH, Martonen TB. Validation of the conceptual anatomical model of the lung airway. J Aerosol Med 2004;17:260-9 (Pubitemid 39299327)
65. Tawhai MH, Pullan AJ, Hunter PJ. Generation of an anatomically based three-dimensional model of the conducting airways. Ann Biomed Eng 2000;28:793-802
66. Martonen TB, Schroeter JD Fleming JS. 3D in-silico modelling of the human respiratory system for inhaled drug delivery and imaging analysis. J Pharm Sci 2007;96:603-17 (Pubitemid 46466082)
67. Fleming JS, Conway JH, Holgate ST, et al. Comparison of methods for deriving aerosol deposition by aerosol generation from three-dimensional radionuclide imaging. J Aerosol Sci 2000;31:1251-9 (Pubitemid 30479790)
68. Eberl S, Chan H-K, Daviskas E, et al. Aerosol deposition and clearance measurement: a novel technique using dynamic SPET. Eur J Nucl Med 2001;28:1365-72
69. Hill DLG, Hawkes DJ, Crossman JF, et al. Registration of MR and CT images for skull base surgery using point like anatomical features. Brit J Radiol 1991;64:1030-5
70. Hawkes DJ. Algorithms for radiological image registration and their clinical applications. J Anat 1998;193:347-61 (Pubitemid 28534891)
71. Kyme AZ, Hutton BF, Hatton RL, et al. Practical aspects of a data-driven motion correction approach for brain SPECT. IEEE Trans Med Imaging 2003;22:722-9
72. Pitcairn G, James J, Joyson A, et al. TechneCoat: a novel method for radiolabelling dry powder formulations in radionuclide imaging studies. In: Dalby RN, Byron PR, Peart J, et al. editors, Respiratory Drug Delivery VIII. Davis Horwood, Raleigh; 2002. p. 553-6
73. Ito H, Pitcairn G, Hirst P, et al. An in vivo study to assess the suitability of Technegas as a SPECT imaging agent for pulmonary drug formulations. In: Dalby RN, Byron PR, Peart J, et al, editors, Respiratory Drug Delivery VIII. Davis Horwood, Raleigh; p. 439-42
74. Chan H-K, Eberl S, Daviskas E, et al. Changes in lung deposition of aerosols due to hygroscopic growth. A fast SPECT study. J Aerosol Med 2002;15:307-11 (Pubitemid 34983137)
75. Conway JH, Walker P, Fleming JS, et al. Three-dimensional description of the deposition of inhaled terbutaline sulphate administered via Turbuhaler. In: Dalby RN, Byron PR, Farr SJ, et al, editors, Respiratory Drug Delivery VII. Serentec Press, Raleigh; 2000. p. 607-9
76. Bajc M, Neilly JB, Miniati M, et al. EANM guidelines for ventilation/ perfusion scintigraphy: part 1 pulmonary imaging with ventilation/perfusion single photon emission tomography. Eur J Nucl Med 2009;36:1356-70
77. Bennett WD, Daviskas E, Hasani A, et al. Mucociliary and cough clearance as a biomarker for therapeutic development. J Aerosol Med Pulm Drug Deliv 2010;23:261-72
78. Rhodes CG, Hughes JMB. Pulmonary studies using positron emission tomography. Eur Respir J 1995;8:1001-17
79. Lee Z, Berridge MS. PET imaging-based evaluation of aerosol drugs and their delivery devices: nasal and pulmonary studies. IEEE Trans Med Imaging 2002;21:1324-31
80. Dolovich MB. 18F-fluorodeoxyglucose positron emission tomographic imaging of pulmonary functions, pathology, and drug delivery. Proc Am Thorac Soc 2009;6:477-85
81. Bailey DL. Imaging the airways in 2006. J Aerosol Med 2006;19:1-7
82. Lee Z, Berridge MS, Finlay WH, Heald DL. Mapping PET-measured triamcinolone acetonide aerosol distribution into deposition by airway generation. Int J Pharm 2000;199:7-16 (Pubitemid 30224500)
83. Weinberg BD, Schomisch SA, Rahmatall M, et al. Mapping of PET-measured aerosol deposition: a comparison study. J Aerosol Sci 2005;36:1157-76 (Pubitemid 41135904)
84. Pike VW. The status of PET radiochemistry for drug development and evaluation. Drug Inform J 1997;31:997-1013 (Pubitemid 27360444)
85. Aboagye EO, Price PM, Jones T. In vivo pharmacokinetics and pharmacodynamics in drug development using positron-emitting tomography. Drug Discov Today 2001;6:293-302 (Pubitemid 32194666)
86. Berridge MS, Lee Z, Heald DL. Pulmonary distribution and kinetics of inhaled 11C triamcinolone acetonide. J Nucl Med 2000;41:1603-11
87. Constantinou M, Waters SL, Steel CJ, et al. Flixotide pressurized metered dose inhalers loaded with 18F-fluticasone dipropionate particles for drug deposition studies in humans with PET - formulation and analysis. J Label Comp Radiopharm 2004;47:55-70 (Pubitemid 38166413)
88. Basu S, Alavi A. Unparalleled contribution of 18F-FDG PET to medicine over 3 decades. J Nucl Med 2008;49:17N-21N and 37N
89. Yanai M, Hatazawa J, Ojima F, et al. Deposition and clearance of inhaled 18FDG powder in patients with chronic obstructive pulmonary disease. Eur Respir J 1998;11:1342-8 (Pubitemid 28298599)
90. Dolovich M, Labiris R. Imaging drug delivery and drug responses in the lung. Proc Am Thorac Soc 2004;1:329-37
91. Berridge MS, Heald DL, Lee Z. Imaging studies of biodistribution and kinetics in drug development. Drug Dev Res 2003;59:208-26 (Pubitemid 36899890)
92. Martin AR, Thompson RB, Finlay WH. MRI measurement of regional lung deposition in mice exposed nose-only to nebulized superparamagnetic iron oxide particles. J Aerosol Med Pulm Drug Deliv 2008;21:335-42
93. Martin AR, Redman GES, Waszak P, et al. Influence of an externally applied magnetic field on the regional deposition patterns of iron oxide loaded high aspect ratio particles in mechanically ventilated rabbits. In: Dalby RN, Byron PR, Peart J, et al. editors, Respiratory Drug Delivery 2010. Davis Healthcare International, River Grove; p. 785-9
94. Thiel CG. Can in vitro particle size measurements be used to predict pulmonary deposition of aerosol from inhalers? J Aerosol Med 1998;11(Suppl 1):S43-52 (Pubitemid 28286032)
95. Finlay WH, Martin AR. Recent advances in predictive understanding of respiratory tract deposition. J Aerosol Med Pulm Drug Deliv 2008;21:189-206
96. Byron PR, Hindle M, Lange CF, et al. In vivo-in vitro correlations: predicting pulmonary drug deposition from pharmaceutical aerosols. J Aerosol Med Pulm Drug Deliv 2010;23(Suppl 2):S59-69
97. Martonen TB, Musante CJ, Segal RA, et al. Lung models: strengths and limitations. Respir Care 2000;45:712-36 (Pubitemid 30484810)
98. Martonen TB, Smyth HD, Isaacs KK, Burton RT. Issues in drug delivery: concepts and practice. Respir Care 2005;50:1228-52